Study Name Population Protocol
ApcinteX/SerpinPC/AP-0102 PRESent2

Haemophilia A & B, with and without inhibitors

A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

GT4BD

Newly referred patients with suspected inherited bleeding disorder

https://bmjopen.bmj.com/content/15/4/e102041

SeroCanAAV

Male participants 18 years or older, with mild, moderately severe to severe hemophilia B

A Canada-Wide Hemophilia B Biobanking Initiative and an Independent Observational Study of AAV5 Neutralizing Antibody Seroprevalence and Seroconversion in the Canadian Hemophilia B Population

In this section